Several states are cutting or considering limits to programs that help people access HIV medications as federal funding has failed to keep pace with rising costs, according to a February 2026 ADAP Watch report from the National Association of State and Territorial AIDS Directors (NASTAD). The report warns federal appropriations for the Ryan White HIV/AIDS Program and related supports have “remained relatively unchanged over the last decade,” even as enrollment and drug prices have increased, leaving states to cover growing budget gaps.
What states are doing
– At least 18 states have already implemented cost‑containment measures, and more than 20 have adopted or are considering restrictions.
– Common changes include lowering income eligibility thresholds, narrowing formularies, restricting drug coverage, tightening enrollment or recertification rules, and reducing insurance premium assistance.
Examples
– Florida cut ADAP eligibility from 400% to 130% of the federal poverty level, a change estimated to affect more than 12,000 clients. The state also stopped covering the single‑tablet regimen Biktarvy and limited Descovy coverage to patients with specific clinical needs.
– Pennsylvania lowered eligibility from 500% to 350% of the federal poverty level, affecting roughly 1,600 clients.
– Kansas reduced premium‑assistance eligibility from 400% to 250% of the federal poverty level.
– Delaware and Rhode Island have also reduced eligibility caps.
– Arizona, Michigan, and Nevada have tightened recertification or pared back formularies.
– Alaska and Oklahoma reinstated stricter six‑month recertification policies.
Why this matters
ADAPs provide antiretroviral therapy and insurance assistance for low‑ and middle‑income people living with HIV. Consistent treatment leads to viral suppression, protecting individual health and preventing transmission. Reductions in eligibility, covered drugs, or insurance help could disrupt access to medications. Interrupting treatment allows HIV to replicate again, weakening the immune system, increasing the risk of serious illness, and raising the chance of drug resistance—potentially limiting future treatment options and undermining progress in viral suppression at the population level.
Funding context and reactions
The report links these state actions to flat federal funding for HIV programs despite increases in need and cost. Broader federal cuts to research and prevention have compounded fiscal pressures. Advocacy groups emphasize that sustained federal investment is critical to maintaining treatment access and ending the epidemic. Carl Baloney Jr., president and CEO of AIDS United, said major federal investment in HIV prevention, treatment, and support services is essential in every jurisdiction, noting that preventing infections saves money over time: each HIV infection prevented avoids an estimated half‑million dollars in lifetime treatment costs.
Implications
State cost‑containment measures may leave many people without direct access to antiretroviral medications or insurance premium assistance, increasing the burden on clinics and community providers and risking worse health outcomes and higher long‑term costs. Observers warn that cutting public health infrastructure now could lead to greater expenses and harm later if treatment access deteriorates and transmission increases.
